非透析CKD试验标准治疗组GFR下降的 secular 趋势
该meta分析纳入92项RCT的标准治疗组共32202例成人CKD患者,评估过去30年GFR下降速率的 secular 趋势。总体年均GFR下降为-4.00(95%CI -4.55至-3.44)mL/min/1.73m2,异质性高(I2=98.4%)。按发表年代,1991-2000、2001-2010、2011-2023的年均下降分别为-5.44、-3.92、-3.20 mL/min/1.73m2,呈随时间减小趋势。
要点
- 标准治疗组年均GFR下降为-4.00 mL/min/1.73m2(95%CI -4.55至-3.44)。
- 1991-2000、2001-2010、2011-2023年GFR下降分别为-5.44、-3.92、-3.20 mL/min/1.73m2/年。
- 发表年份与GFR下降减少相关(β=0.09,95%CI 0.032-0.148,P=0.003)。
核心结论
- 过去30年,接受标准治疗的RCT入组CKD患者GFR下降速率随时间减小。
研究设计与样本
- 系统综述与meta分析,将RCT标准治疗组作为观察性数据分析。
- 纳入92项以GFR下降为结局的3期RCT标准治疗组,共32202例成人CKD患者。
- 采用随机效应模型合并GFR下降均值,并用meta回归分析异质性来源。
主要发现
- 标准治疗组总体年均GFR下降为-4.00(95%CI -4.55至-3.44)mL/min/1.73m2,异质性高(I2=98.4%[95%CI 98.2-98.5],P<0.001)。
- 按发表年代,1991-2000、2001-2010、2011-2023的年均GFR下降分别为-5.44(95%CI -7.15至-3.73)、-3.92(95%CI -4.82至-3.02)、-3.20(95%CI -3.75至-2.64)mL/min/1.73m2。
- meta回归显示发表年份与GFR下降减少相关(β=0.09[95%CI 0.032-0.148],P=0.003)。
- meta回归显示GFR下降的异质性主要由年龄和蛋白尿解释。
临床怎么用
- 在临床试验中实施的标准肾脏照护可能与改善的临床结局相关。
- 这些数据可为未来肾脏病学RCT的设计提供参考。
局限性
- 所选试验中评估GFR的方法不同。
- 研究为观察性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: The standard of care (SoC) group of randomized controlled trials (RCTs) is a useful setting to explore the secular trends in kidney disease progression because implementation of best clinical practices is pursued for all patients enrolled in trials. This meta-analysis evaluated the secular trend in the change of glomerular filtration rate (GFR) decline in the SoC arm of RCTs in chronic kidney disease (CKD) published in the last 30 years. STUDY DESIGN: Systematic review and meta-analysis of the SoC arms of RCTs analyzed as an observational study. SETTING & STUDY POPULATIONS: Adult patients with CKD enrolled in the SoC arm of RCTs. SELECTION CRITERIA FOR STUDIES: Phase 3 RCTs evaluating GFR decline as an outcome in SoC arms. DATA EXTRACTION: Two independent reviewers evaluated RCTs for eligibility and extracted relevant data. ANALYTICAL APPROACH: The mean of GFR declines extracted in the SoC arm of selected RCTs were pooled by using a random effects model. Meta-regression analyses were performed to identify factors that may explain heterogeneity. RESULTS: The SoC arms from 92 RCTs were included in the meta-analysis with a total of 32,202 patients. The overall mean GFR decline was-4.00 (95% CI, -4.55 to-3.44) mL/min/1.73m2 per year in the SoC arms with a high level of heterogeneity (I2, 98.4% [95% CI, 98.2-98.5], P<0.001). Meta-regression analysis showed an association between publication year (β estimate, 0.09 [95% CI, 0.032-0.148], P=0.003) and reduction in GFR over time. When evaluating publication decade categorically, GFR decline was-5.44 (95% CI, -7.15 to-3.73), -3.92 (95% CI, -4.82 to-3.02), and -3.20 (95% CI, -3.75 to -2.64) mL/min/1.73m2 per year during 1991-2000, 2001-2010, and 2011-2023, respectively. Using meta-regression, the heterogeneity of GFR decline was mainly explained by age and proteinuria. LIMITATIONS: Different methods assessing GFR in selected trials and observational design of the study. CONCLUSIONS: In the last 3 decades, GFR decline has decreased over time in patients enrolled in RCTs who received the standard of care. TRIAL REGISTRATION: Registered at PROSPERO with record number CRD42022357704. PLAIN-LANGUAGE SUMMARY: This study evaluated the secular trend in the change in glomerular filtration rate (GFR) decline in the placebo arms of randomized controlled trials (RCTs) that were studying approaches to protect the kidneys in the setting of chronic kidney disease. The placebo groups of RCTs are useful for examining whether the rate of progression of kidney disease has changed over time. We found an improvement in the slope of change in GFR over time. These findings suggest that adherence to standards of kidney care as implemented in clinical trials may be associated with improved clinical outcomes, and these data may inform the design of future RCTs in nephrology.
引用
- Garofalo C, Borrelli S, Liberti ME, et al. Secular Trend in GFR Decline in Non-Dialysis CKD Based on Observational Data From Standard of Care Arms of Trials. Am J Kidney Dis. 2023. PMID: 37956953. doi:10.1053/j.ajkd.2023.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。